Back to Search Start Over

Developing Treatment Guidelines During a Pandemic Health Crisis: Lessons Learned From COVID-19.

Authors :
Kuriakose S
Singh K
Pau AK
Daar E
Gandhi R
Tebas P
Evans L
Gulick RM
Lane HC
Masur H
Aberg JA
Adimora AA
Baker J
Kreuziger LB
Bedimo R
Belperio PS
Cantrill SV
Coopersmith CM
Davis SL
Dzierba AL
Gallagher JJ
Glidden DV
Grund B
Hardy EJ
Hinkson C
Hughes BL
Johnson S
Keller MJ
Kim AY
Lennox JL
Levy MM
Li JZ
Martin GS
Naggie S
Pavia AT
Seam N
Simpson SQ
Swindells S
Tien P
Waghmare AA
Wilson KC
Yazdany J
Zachariah P
Campbell DM
Harrison C
Burgess T
Francis J
Sheikh V
Uyeki TM
Walker R
Brooks JT
Ortiz LB
Davey RT Jr
Doepel LK
Eisinger RW
Han A
Higgs ES
Nason MC
Crew P
Lerner AM
Lund C
Worthington C
Source :
Annals of internal medicine [Ann Intern Med] 2021 Aug; Vol. 174 (8), pp. 1151-1158. Date of Electronic Publication: 2021 Jun 15.
Publication Year :
2021

Abstract

The development of the National Institutes of Health (NIH) COVID-19 Treatment Guidelines began in March 2020 in response to a request from the White House Coronavirus Task Force. Within 4 days of the request, the NIH COVID-19 Treatment Guidelines Panel was established and the first meeting took place (virtually-as did subsequent meetings). The Panel comprises 57 individuals representing 6 governmental agencies, 11 professional societies, and 33 medical centers, plus 2 community members, who have worked together to create and frequently update the guidelines on the basis of evidence from the most recent clinical studies available. The initial version of the guidelines was completed within 2 weeks and posted online on 21 April 2020. Initially, sparse evidence was available to guide COVID-19 treatment recommendations. However, treatment data rapidly accrued based on results from clinical studies that used various study designs and evaluated different therapeutic agents and approaches. Data have continued to evolve at a rapid pace, leading to 24 revisions and updates of the guidelines in the first year. This process has provided important lessons for responding to an unprecedented public health emergency: Providers and stakeholders are eager to access credible, current treatment guidelines; governmental agencies, professional societies, and health care leaders can work together effectively and expeditiously; panelists from various disciplines, including biostatistics, are important for quickly developing well-informed recommendations; well-powered randomized clinical trials continue to provide the most compelling evidence to guide treatment recommendations; treatment recommendations need to be developed in a confidential setting free from external pressures; development of a user-friendly, web-based format for communicating with health care providers requires substantial administrative support; and frequent updates are necessary as clinical evidence rapidly emerges.

Details

Language :
English
ISSN :
1539-3704
Volume :
174
Issue :
8
Database :
MEDLINE
Journal :
Annals of internal medicine
Publication Type :
Academic Journal
Accession number :
34125574
Full Text :
https://doi.org/10.7326/M21-1647